-
Oct 30, 2024 | 
targetedonc.com | Yazan Madanat
The FDA has warned against using BioZorb Markers due to potential adverse effects (AEs), following Hologic’s recall of all unused devices. Patients report pain, infection, device migration, and other complications, sometimes requiring additional treatment or device removal. Patients with implants should contact providers if symptomatic; radiation therapy risks should be discussed with providers.
-
Jul 9, 2024 | 
newsbreak.com | Yazan Madanat
Welcome to NewsBreak, an open platform where diverse perspectives converge. Most of our content comes from established publications and journalists, as well as from our extensive network of tens of thousands of creators who contribute to our platform. We empower individuals to share insightful viewpoints through short posts and comments.
-
Jul 9, 2024 | 
targetedonc.com | Yazan Madanat
DSP-5336 delivered positive results in a recent ongoing, first-in-human, phase 1/2 study, particularly for patients with acute leukemia with certain genetic markers, according to findings presented at the European Hematology Association (EHA) 2024 Hybrid Congress (NCT04988555).1Results from this study included data from 57 patients who received various doses of DSP-5336.
-
Feb 5, 2024 | 
targetedonc.com | Yazan Madanat
Research plays a pivotal role in the continually evolving treatment landscape for myelodysplastic syndrome [MDS].
-
Dec 22, 2023 | 
targetedonc.com | Yazan Madanat
2 Clarke Drive Cranbury, NJ 08512
-
Sep 26, 2023 | 
futuremedicine.com | Talha Badar |Yazan Madanat |Amer M Zeidan
T Badar served on an advisory board for Pfizer and Takeda. T Badar received travel reimbursement from DAVA Oncology and Cardinal Health. YF Madanat has received honoraria/consulting fees from Blueprint Medicines, GERON, OncLive and MD Education. YF Madanat participated in advisory boards and received honoraria from Sierra Oncology, Stemline Therapeutics, Blueprint Medicines, Morphoses, Taiho Oncology, Rigel Pharmaceuticals and Novartis.
-
Aug 3, 2023 | 
onclive.com | Rami D. Komrokji |Andrew Brunner |Hetty Carraway |Yazan Madanat |Amer M Zeidan
EP: 1.Diagnosing Myelodysplastic Syndromes (MDS) EP: 2.Risk Stratification of MDS EP: 3.First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia EP: 4.Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia EP: 5.Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia EP: 6.Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia EP: 7.Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia EP: 8.Treatment...
-
Jul 28, 2023 | 
onclive.com | Rami D. Komrokji |Andrew Brunner |Hetty Carraway |Yazan Madanat |Amer M Zeidan
Luspatercept for Lower-Risk MDS: Data From the COMMANDS TrialRami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.
-
Jul 28, 2023 | 
onclive.com | Rami D. Komrokji |Andrew Brunner |Hetty Carraway |Yazan Madanat |Amer M Zeidan
Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.
-
Jul 20, 2023 | 
onclive.com | Rami D. Komrokji |Andrew Brunner |Hetty Carraway |Yazan Madanat |Amer M Zeidan
The panel discusses the patient profile of a man with lower-risk MDS and how they would have approached treatment in their practice.
